Phaseline

Companies › Guangdong Hengrui Pharmaceutical

Guangdong Hengrui Pharmaceutical: clinical trials, targets and expected readouts

12 active drug programs in 26 registered trials: 16 Phase 2, 5 Phase 1, 5 Phase 3; Immunology, Respiratory, Neurology, Genitourinary; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SHR-1819 Injection
IL-4 receptor alpha inhibitor
IL4RPhase 3Seasonal Allergic Rhinitis; Adolescents With Moderate-to-severe Atopic Dermatitis; Moderate-to-severe Atopic Dermatitis; Prurigo NodularisDec 2026
SHR-1905
IL-4 receptor alpha antagonist
–Phase 3Asthma; Chronic Rhinosinusitis With Nasal Polyps; Moderate-to-severe Atopic DermatitisFeb 2027
SHR-1703 Injection
IL-5 receptor alpha antagonist
IL5RAPhase 3Asthma With Eosinophilic Phenotype; Eosinophilic Asthma Patients; Eosinophilic Granulomatosis With PolyangiitisSep 2027
HRS-9821 Inhalation Suspension–Phase 2COPDNov 2026
SHR-2173 Injection–Phase 2Primary IgA Nephropathy; Active Lupus Nephritis; Primary Membranous Nephropathy; Generalized Myasthenia Gravis …Nov 2026
SHR-1139 injection–Phase 2Moderate to Severe Plaque Psoriasis; Psoriasis; Adult Patients With Moderately to Severely Active Ulcerative ColitisDec 2026
HRS-9813–Phase 2IPF and PPFJun 2028
SHR-3045 Injection–Phase 2Moderate to Severe Active Rheumatoid Arthritis–
SHR-7590–Phase 1Moderate-to-severe Inflammatory Bowel DiseaseJan 2027
SHR-7012 injection–Phase 1Cutaneous Lupus Erythematosus(CLE)Apr 2027
SHR-4712–Phase 1Advanced Solid TumorMay 2027
HRS-9821 Powder for Inhalation–Phase 1COPD–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06875934SHR-1139 injectionPhase 2Moderate to Severe Plaque PsoriasisImmunologyNov 2025
NCT07233655SHR-3045 InjectionPhase 2Moderate to Severe Active Rheumatoid ArthritisImmunologyApr 2026
NCT07567872HRS-9821 Powder for InhalationPhase 1COPDRespiratorySep 2026
NCT07206758SHR-2173 InjectionPhase 1Immune ThrombocytopeniaHematologyNov 2026
NCT07640451HRS-9821 Inhalation SuspensionPhase 2COPDRespiratoryNov 2026
NCT07688772SHR-1819 InjectionPhase 3Seasonal Allergic RhinitisImmunologyDec 2026
NCT07719530SHR-1139 injectionPhase 2PsoriasisImmunologyDec 2026
NCT07758101SHR-7590Phase 1Moderate-to-severe Inflammatory Bowel DiseaseImmunologyJan 2027
NCT07211542SHR-1905Phase 2Moderate-to-severe Atopic DermatitisImmunologyFeb 2027
NCT07354932SHR-2173 InjectionPhase 2Primary IgA NephropathyGenitourinaryApr 2027
NCT07749651SHR-7012 injectionPhase 1Cutaneous Lupus Erythematosus(CLE)ImmunologyApr 2027
NCT06993116SHR-4712Phase 1Advanced Solid TumorOncologyMay 2027
NCT07229742SHR-2173 InjectionPhase 2Active Lupus NephritisImmunologyJun 2027
NCT07321951SHR-1819 InjectionPhase 2Moderate-to-severe Atopic DermatitisImmunologyJun 2027
NCT07289763SHR-2173 InjectionPhase 2Primary Membranous NephropathyGenitourinaryAug 2027
NCT07232576SHR-1139 injectionPhase 2Adult Patients With Moderately to Severely Active Ulcerative ColitisImmunologyAug 2027
NCT07622342SHR-2173 InjectionPhase 2Generalized Myasthenia GravisNeurologySep 2027
NCT06653322SHR-1703 InjectionPhase 3Asthma With Eosinophilic PhenotypeRespiratorySep 2027
NCT07309055SHR-1819 InjectionPhase 3Adolescents With Moderate-to-severe Atopic DermatitisImmunologyNov 2027
NCT07098403SHR-1905Phase 3AsthmaRespiratoryJan 2028
NCT07299422SHR-2173 InjectionPhase 2Systemic Lupus ErythematosusImmunologyMar 2028
NCT07132827SHR-1905Phase 3Chronic Rhinosinusitis With Nasal PolypsRespiratoryApr 2028
NCT07192939HRS-9813Phase 2IPF and PPFRespiratoryJun 2028
NCT06441812SHR-1703 InjectionPhase 2Eosinophilic Asthma PatientsRespiratorySep 2028
NCT06554509SHR-1819 InjectionPhase 2Prurigo NodularisImmunologyOct 2028
NCT05979051SHR-1703 InjectionPhase 2Eosinophilic Granulomatosis With PolyangiitisImmunologyDec 2028

Targets

IL4R (1) IL5RA (1)

Companies with the same targets

Sanofi Apogee Therapeutics Keymed Biosciences Co.Ltd Regeneron Pharmaceuticals Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Innovent Biologics (Suzhou) Uniquity One (UNI) Jiangsu Genscend Biopharmaceutical Genrix (Shanghai) Biopharmaceutical AstraZeneca

Companies built like this

Apogee Therapeutics Sunshine Guojian Pharmaceutical (Shanghai) Jiangsu Genscend Biopharmaceutical Teva Branded Pharmaceutical Products R&D Prana Therapies

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.